Indeed, it has been demonstrated that TRPV4-mediated Ca2+ influx upon stimulation with the selective agonist GSK1016790 A, is able to promote cell migration of glioma cells (Ou-yang et al., 2018), a similar mechanism previously reported in breast cancer (Lee et al., 2017). Here, TRPV4 is linked to glioma.